Copper histidinate (Zycubo) is primarily used for the treatment of rare pediatric diseases, but its safety and medication considerations differ significantly among populations with different physiological states and age groups.

I. Key Points for Pediatric Use

1. Applicable Age and Efficacy

(1) Copper histidinate has been confirmed to be effective and safe in pediatric patients with Menkes disease, and relevant information is included in the dosing guidance across all age groups.

(2) The dosing regimen is strictly stratified by age: twice daily for patients younger than 1 year, and once daily for patients aged 1 year to under 17 years, with a dose of 1.45 mg each time.

2. Toxicity Warnings from Juvenile Animal Studies

(1) In juvenile rat studies (corresponding to human neonatal to adult stages), pathological changes were observed in the kidneys (renal tubular necrosis, eosinophilic globules), liver (single-cell necrosis, inflammation, fibrosis), and spleen (cellular hyperplasia, pigment-laden macrophages) after administration.

(2) Elevations in liver enzymes, bilirubin, and decreases in red blood cells, hemoglobin, and hematocrit were more pronounced at higher exposure levels.

(3) Renal and hepatic changes were also observed in the low-dose group, suggesting that juvenile individuals have poorer tolerance to copper accumulation.

3. Special Risks in Infants and Toddlers

(1) The risk of copper accumulation-related toxicity is higher during the first two years of life due to the immature renal and hepatic functions.

(2) Caregivers must closely cooperate with the monitoring plan to detect abnormal laboratory parameters early.

II. Considerations for Pregnancy and Lactation

1. Pregnancy Risk Information

There are currently no clinical data on the use of Zycubo in pregnant women to assess the risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes associated with the drug.

2. Unknowns in Lactation

(1) Data are lacking on whether copper histidinate or its metabolites are present in human or animal milk, their effects on breastfed infants, or their impact on milk production.

(2) When deciding on breastfeeding, the infant's developmental benefits, the mother's clinical need for Zycubo, and the potential adverse effects of the drug or underlying disease on the infant should be comprehensively considered.

III. Elderly Population and Other Precautions

1. Use in the Elderly

Menkes disease is a pediatric-specific condition, and clinical studies did not include patients aged 65 years and older; therefore, there is no experience regarding the safety and efficacy of this product in the elderly population.

2. Uncovered Indication Populations

(1) This product is explicitly not indicated for the treatment of Occipital Horn Syndrome.

(2) Although this condition also involves copper metabolism abnormalities, its pathological mechanism differs from that of Menkes disease and should not be confused in use.

3. Genotype and Population Differences

(1) The clinical trials predominantly included pediatric patients carrying severe pathogenic variants of the ATP7A gene (duplications/deletions, nonsense mutations, or splice-site variants), most of whom were male, with a relatively high proportion of preterm births.

(2) These population characteristics reflect the actual epidemiological distribution of Menkes disease and also indicate that the medication experience is mainly based on this specific population.